A Double Blind, Multi-Center, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of 400 mg of Velneperit (S-2367) and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day With a Reduced Calorie Diet (RCD) in Obese Subjects.
Phase of Trial: Phase II
Latest Information Update: 10 May 2018
At a glance
- Drugs Velneperit (Primary) ; Orlistat
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shionogi
- 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 21 May 2010 New trial record